Revenue Recognition (Tables)

6 Months Ended

Jun. 30, 2023

Revenue from Contract with Customer [Abstract]

Schedule of Timing of Revenue Recognition

The following table illustrates the timing of the Company’s revenue recognition patterns:

	Three Months Ended June 30,				Six Months Ended June 30,
	2023		2022		2023		2022
Software products and services – point in time	47.8	%	45.8	%	37.1	%	45.2	%
Software products and services – over time	35.6		32.2		25.0		27.2
Drug Discovery – point in time	—		3.5		27.4		12.2
Drug Discovery – over time	16.6		18.5		10.5		15.4

Schedule of Revenue Recognized from the Sources of Software Products and Services Revenue

The following table presents the revenue recognized from the sources of software products and services revenue:

	Three Months Ended June 30,				Six Months Ended June 30,
	2023		2022		2023		2022
On-premise software	$	16,814	$	16,595	$	36,758	$	38,281
Hosted software	4,451		3,596		8,902		6,851
Software maintenance	5,877		4,952		11,627		9,678
Professional services	2,210		3,868		4,278		7,282
Revenue from contracts with customers	29,352		29,011		61,565		62,092
Software contribution	—		1,000		—		1,000
Total software revenue	$	29,352	$	30,011	$	61,565	$	63,092

Drug Discovery Revenue

The following table presents the revenue recognized from the sources of drug discovery revenue:

	Three Months Ended June 30,				Six Months Ended June 30,
	2023		2022		2023		2022
Drug discovery services revenue from contracts with customers	$	5,232	$	8,019	$	37,035	$	23,259
Drug discovery contribution	605		439		1,371		781
Total drug discovery revenue	$	5,837	$	8,458	$	38,406	$	24,040

Schedule of Contract Balances

Contract balances were as follows:

	As of June 30, 2023		As of December 31, 2022
Contract assets	$	15,289	$	11,378
Deferred revenue, short-term:
Software products and services	26,114		37,085
Drug discovery	20,560		20,846
Deferred revenue, long-term:
Software products and services	1,831		2,526
Drug discovery	13,789		23,072